TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Taiwan Arms Deal on Track Despite U.S.-China Summit Uncertainty 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
US-Iran Ceasefire Talks Underway: What You Need to Know 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump to Visit China in May for High-Stakes Xi Summit Amid Iran War 
G7 Foreign Ministers Gather in France Amid Global Tensions and U.S. Policy Uncertainty 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Trump Seeks Quick End to U.S.-Iran Conflict Amid Ongoing Middle East Tensions 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
